Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Last trade$4.52
Day change-$0.14 (-3.00%)
Day range$4.08 – $4.76
Volume346,746
Market cap$475M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$474.59M
Price / earnings
—
Price / book
2.45×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.01×
Profitability
Earnings per share
-$0.66
Return on assets
-32.56%
Return on equity
-34.97%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
15.8×
Quick ratio
15.8×
Cash ratio
4.84×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$49.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for STTK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$1M
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$1M
$0
$0
$0
Selling, general and administrative
$5.48M
$4.46M
$4.6M
$4.32M
$4.1M
$4.35M
$4.47M
$4.25M
Research and development
$21.57M
$11.7M
$10.95M
$9.06M
$7.62M
$8.68M
$9.92M
$15.4M
Total operating expenses
$27.05M
$16.16M
$15.55M
$13.37M
$11.72M
$13.03M
$14.39M
$19.64M
Operating income
-$27.05M
-$16.16M
-$15.55M
-$13.37M
-$10.72M
-$13.03M
-$14.39M
-$19.64M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$25.2M
-$15.15M
-$14.77M
-$12.59M
-$10.06M
-$12.46M
-$13.7M
-$18.68M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$25.2M
-$15.15M
-$14.77M
-$12.59M
-$10.06M
-$12.46M
-$13.7M
-$18.68M
Net income attributable to common shareholders
-$25.2M
-$15.15M
-$14.77M
-$12.59M
-$10.06M
-$12.46M
-$13.7M
-$18.68M
EBITDA
-$26.23M
-$15.3M
-$14.65M
-$12.47M
-$9.8M
-$12.1M
-$13.45M
-$18.7M
Basic earnings per share
-$0.14
-$0.12
-$0.13
-$0.12
-$0.14
-$0.24
-$0.27
-$0.37
Diluted earnings per share
-$0.14
-$0.12
-$0.13
-$0.12
-$0.14
-$0.24
-$0.27
-$0.37
Recent news
Company coverage with links to the original publishers.
Denali Therapeutics reported a Q3 loss of $0.64 per share, beating consensus estimates of $0.69 loss, with an earnings surprise of +7.25%. The company posted revenues of $17.78 million, surpassing revenue estimates by 41.88% compared to zero revenues a year ago. The stock has gained 14.2% year-to-date, outperforming the S&P 500's 10.2% gain. Denali holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Shattuck Labs (STTK) gained nearly 5% on Monday following positive analyst coverage from two firms. TD Cowen initiated a buy rating while Raymond James issued a strong buy with an $18 price target (more than double the $7.90 closing price). The optimism centers on the company's lead drug candidate SL-325, a first-in-class autoimmune and inflammatory disease treatment currently in Phase 2b clinical testing for inflammatory bowel disease, with analysts estimating a $20+ billion addressable market.
Shattuck Labs stock rose nearly 5% on Friday following JPMorgan Chase analyst Brian Cheng's initiation of coverage with an 'overweight' rating and $10 price target (35% upside). The bullish call was driven by positive clinical trial data for the company's lead drug candidate SL-325, a first-in-class antagonist antibody for inflammatory bowel disease, which showed a cleaner safety profile and stronger target engagement than competitors. The drug is scheduled to enter Phase 2 trials in Q3.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced the pricing of a $75 million public offering consisting of 10.88 million shares at $4.00 per share and 7.87 million pre-funded warrants at $3.9999 per warrant. The offering is expected to close on June 11, 2026, with underwriters including Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor.
Shattuck Labs, a clinical-stage biotechnology company developing DR3 blocking antibodies, announced the pricing of a public offering of 10.9 million shares at $4.00 per share and 7.9 million pre-funded warrants at $3.9999 per warrant, expected to raise approximately $75 million gross proceeds. The offering is expected to close on June 11, 2026, with Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor serving as joint bookrunning managers.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.